Heron Therapeutics Inc (HRTX)’s Stock Is Buy After Today’s Huge Increase

September 17, 2017 - By Marguerite Chambers

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! The stock increased 5.12% or $0.75 on September 15, reaching $15.4. About 1.20M shares traded or 142.29% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 20.92% since September 17, 2016 and is downtrending. It has underperformed by 37.62% the S&P500.
The move comes after 7 months positive chart setup for the $833.74 million company. It was reported on Sep, 17 by Barchart.com. We have $16.02 PT which if reached, will make NASDAQ:HRTX worth $33.35 million more.

Investors wait Heron Therapeutics Inc (NASDAQ:HRTX) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.87 EPS, up $0.37 or 29.84 % from last year’s $-1.24 same quarter earnings. Heron Therapeutics Inc’s Wall Street analysts see 8.75 % negative EPS growth, taking into account the $-0.80 EPS reproted in the previous quarter,

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Among 10 analysts covering Heron Therapeutics (NASDAQ:HRTX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 19 analyst reports since August 3, 2015 according to SRatingsIntel. Jefferies maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Monday, June 12 with “Buy” rating. The firm earned “Buy” rating on Monday, August 10 by Brean Capital. The stock has “Buy” rating by Lake Street on Thursday, December 10. The firm earned “Buy” rating on Thursday, August 10 by Noble Financial. As per Wednesday, September 2, the company rating was initiated by Bank of America. The rating was maintained by Jefferies on Thursday, July 13 with “Buy”. The rating was initiated by Aegis Capital with “Buy” on Wednesday, October 26. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, September 23 report. The firm has “Buy” rating by Cowen & Co given on Friday, May 26. Aegis Capital maintained the shares of HRTX in report on Thursday, June 1 with “Buy” rating.

More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron Therapeutics: CINV Franchise Provides Valuation Floor, Significant …” on February 04, 2017, also Businesswire.com with their article: “Heron Therapeutics Reports Financial Results for the Three and Six Months …” published on August 09, 2017, Seekingalpha.com published: “Heron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market” on July 10, 2017. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “Heron Therapeutics: Our Next Pick” published on August 14, 2017 as well as Seekingalpha.com‘s news article titled: “Heron Therapeutics: Giving A ‘Thumbs Up’ To This ~$14 Biopharma Stock” with publication date: February 27, 2017.

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has market cap of $833.74 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.